GENB
NASDAQGenerate Biomedicines Inc.
$12.80-0.06 (-0.47%)
News24/Ratings6
Price$12.80-0.04 (-0.35%)
2026-02-272026-04-24
News · 26 weeks24-83%
2025-11-022026-04-26
Mix2490d
- Insider17(71%)
- Analyst6(25%)
- SEC Filings1(4%)
Latest news
24 items- ANALYSTH.C. Wainwright initiated coverage on Generate Biomedicines with a new price targetH.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00
- ANALYSTPiper Sandler initiated coverage on Generate Biomedicines with a new price targetPiper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00
- ANALYSTMorgan Stanley initiated coverage on Generate Biomedicines with a new price targetMorgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00
- ANALYSTCantor Fitzgerald initiated coverage on Generate BiomedicinesCantor Fitzgerald initiated coverage of Generate Biomedicines with a rating of Overweight
- ANALYSTGuggenheim initiated coverage on Generate Biomedicines with a new price targetGuggenheim initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $30.00
- ANALYSTGoldman initiated coverage on Generate Biomedicines with a new price targetGoldman initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $26.00
- INSIDERNew insider Pioneering Medicines 02, Llc claimed ownership of 1,562,500 shares (SEC Form 3)3 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief Executive Officer Nally Michael bought $240,000 worth of shares (20,000 units at $12.00), increasing direct ownership by 4% to 572,707 units (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Vessey Rupert4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief People Officer Grous Beth bought $4,800 worth of shares (300 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Arnold Frances4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer & GC Martin Sean4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lee Laurie Anne4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Simonian Nancy A4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERPresident & CFO Silvers Jason bought $32,000 worth of shares (2,000 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Afeyan Noubar converted options into 32,969,159 shares and bought $75,000,000 worth of shares (4,687,500 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Grigoryan Gevorg4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief Executive Officer Nally Michael converted options into 658,327 shares (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Bancel Stephane converted options into 724,160 shares (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Mendillo Jane L bought $24,000 worth of shares (1,500 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Fanucci Marsha4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Parker Paul Gray4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Afeyan Noubar converted options into 32,969,159 shares and bought $75,000,000 worth of shares (4,687,500 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- SECGenerate Biomedicines Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Generate Biomedicines, Inc. (0002100782) (Filer)